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The c-kit inhibitor STI571 represents one of the most important treatments for patients with masto-
cytosis. However, intracellular pathways modulated by this compound are not completely deﬁned.
Here, STI571 effect on Protein Kinase C (PKC) regulation is determined in HMC-1 mast cell lines.
STI571 activates PKCd isoform resulting in HMC-1560 apoptosis. The apoptosis observed is PKCd-
dependent, since PKCd-silencing avoids STI571 effect. c-kit inhibition implies nuclear PKCd transloca-
tion characterized by a clear dependence on actin cytoskeleton integrity in HMC-1560 cell line, but not
in HMC-1560,816. Therefore, PKCd modulations can lead to a serious decrease in STI571 treatment-
effectiveness.
 2014 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mast cells (MCs) play a key role in the immune response, either
in allergic or non-allergic inﬂammatory conditions [1]. The uncon-
trolled growth of MCs in one or more visceral organs is called mas-
tocytosis [2–4]. This disease is usually associated with somatic
gain-of-function point mutations within c-kit receptor (CD117).
c-kit is a type III tyrosine kinase (TyrK) receptor expressed in
MCs, hematopoietic progenitors, melanocytes, NK cells and inter-
stitial Cajal cells [5,6]. The most common mutation is the c-
kitD816V, present in Human Mast Cell (HMC)-1560,816 line, resulting
from substitution of valine-816 for aspartate [7–9]. Another impor-
tant mutation is the substitution of glycine-560 for valine (V560G),
present in HMC-1560 and HMC-1560,816 cell lines. The natural ligand
of c-kit is the stem cell factor (SCF). Both mutations, located on c-
kit receptor, imply that these sublines grow in vitro without SCF,
since c-kit is ligand-independent phosphorylated [10–14]. STI571
compound (imatinib mesylate or Gleevec) is a tyrosine kinase
inhibitor that inhibits c-kit activity [15–19]. This compound
induces HMC-1560 cell death, however, is ineffective against
HMC-1560,816 proliferation [16,20].
Protein Kinase C (PKC) is a protein involved in multiple and
different biological events and thus plays a crucial role in cellmetabolism regulation. PKC isoforms have been subdivided into
three groups: (1) classical PKCs (a, b and c), which are calcium
(Ca2+) dependent and activated by diacylglycerol (DAG) or phor-
bol ester; (2) novel PKCs (d, e, g and h), which are Ca2+ indepen-
dent but require DAG or phorbol ester for their activation and
the atypical isoenzymes (f, k and i), which seem to be indepen-
dent of both factors. PKC-induced cell metabolism regulation
would occurs subsequently to its phosphorylation and transloca-
tion from the cytosol to the plasma membrane [21]. Therefore,
PKC translocation is a response of its activation and has been
described in several cellular models. For example, classical PKCs
translocate to the membrane in response to an antigen stimulus
in RBL-2H3 mast cell line [22,23]. However, PKC can translocates
also to the nucleus depending on the stimulus [24,25]. In fact,
PKC localization in the nucleus is usually associated with a role
on apoptotic cell death, since PKC has been associated with this
process and subsequently with caspases activation in several cel-
lular types, including MCs [26–30].
In a previous study, the relationship between the tyrosine
kinase inhibitor STI571 and PKC was study in terms of cytotoxic
effect assessment on both HMC-1 cell lines [31]. Here, the effect
of STI571 on PKC activated cells and the relationship between
STI571-induced cell death and PKC activation will be determined
in HMC-1560 and HMC-1560,816 cell lines. With the objective to clar-
ify STI571 mechanism of action, the direct effect of this compound
over PKC will be determined and PKC translocation will be
assessed by measuring cytosolic, nuclear and plasma membrane
PKC levels by Western blot.
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2.1. Chemicals
STI571 was provided by Dr. Luis Escribano Mora (Centro de
Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen
del Carmen, Toledo, Spain). Phorbol 12-myristate 13-acetate
(PMA), latrunculin A derived from Negombata magniﬁca, bovine
serum albumin (BSA), Tween 20 and anti b-tubulin were from
Sigma–Aldrich (Madrid, Spain). Phosphate buffered saline (PBS)
was from Invitrogen (Barcelona, Spain). Anti PKCd was from BD
Biosciences (Madrid, Spain). Anti Mouse IgG was purchased from
GE Healthcare (Barcelona, Spain). Anti PKC Clone M110, anti b-
actin, anti Histone H1 and polyvinylidene ﬂuoride (PVDF) mem-
brane were from Millipore (Temecula, USA). Cell Lab ApoScreen™
Annexin V and DNA Prep™ Stain were from Beckman Coulter (Ful-
lerton, CA, USA). Polyacrylamide gels and molecular weight marker
Precision Plus Protein™ Standards Kaleidoscope™ were from Bio-
Rad (Barcelona, Spain). Negative siRNA control (sc-37007) and
PKCd siRNA (sc-36253) were purchased from Santa Cruz Biotech-
nology (CA, USA). GeneSilencer was from Genlantis (San Diego,
CA, USA).
2.2. Cell cultures
HMC-1560 cells were kindly provided by Dr. J. Butterﬁeld (Mayo
Clinic, Rochester, MN) and HMC-1560,816 cells were kindly provided
by Dr. Luis Escribano Mora with permission from Dr. J. Butterﬁeld.
They were maintained in Iscove’s modiﬁed Dulbecco’s medium
(IMDM) (Gibco, Invitrogen, Spain) supplemented with 10% fetal
bovine serum (FBS) (Gibco, Invitrogen, Spain) and 100 IU/mL pen-
icillin + 100 lg/mL streptomycin (Gibco, Invitrogen, Spain) in an
atmosphere containing 5% CO2. The medium was renewed once a
week.
2.3. Cell preparation
HMC-1 cells were incubated with 25 nM STI571, 100 ng/mL
PMA and 200 nM latrunculin during 48 h. It is widely known that
PKC activation can be induced after PMA short-incubation
(10 min). However, in this study, PMA was incubated the same
time as for STI571 in order to evaluate a possible PMA modulator
effect. Then cells were centrifuged (1500 rpm, 5 min, 4 C) and
washed in saline solution. The composition of this solution was
(mM): Na+ 142.3; K+ 5.94; Ca2+ 1; Mg2+ 1.2; Cl 126.2; HCO3
22.85; HPO42 1.2, SO42 1.2 and glucose 1 g/L.
2.4. Western blotting
2.4.1. Cytoplasmic proteins protocol
The cells were resuspended in 80 lL of lysis buffer with the fol-
lowing composition: 50 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 1X complete protease inhibitor (Roche, Spain)
and 1X phosphatase inhibitor cocktail (Roche, Spain). Cells were
centrifuged at 10,000 rpm for 10 min at 4 C and the supernatant
(cytoplasmic fraction) was collected and stored at 20 C.
2.4.2. Nuclear proteins protocol
The cells were resuspended in 500 lL of buffer containing:
10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 5% Triton
X-100, 1X complete protease inhibitor (Roche, Spain) and 1X phos-
phatase inhibitor cocktail (Roche, Spain) at pH 7.9. Cells were cen-
trifuged at 3000 rpm for 10 min at 4 C. The supernatant was kept
out and the pellet was resuspended on ice in 374 lL of buffer
which contains 5 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA,0.5 mM DTT, 26% glycerol (v/v) at pH 7.9 and 26 lL of 4.6 M NaCl
were added. Samples were sonicated four times (10 s). Assay tubes
were refrigerated on ice for 30 min and centrifuged at 13,500 rpm
for 20 min at 4 C. Finally, the supernatant was collected and
stored at 20 C.2.4.3. Membrane proteins protocol
The cells were resuspended in lysis buffer with the following
composition: 50 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA, 1% Tri-
ton X-100, 1X complete protease inhibitor (Roche, Spain) and 1X
phosphatase inhibitor cocktail (Roche, Spain). Samples were sha-
ken and sonicated for 1 min and then refrigerated on ice for
20 min. Then cells were sonicated 10 s/three times and then centri-
fuged (12,000 rpm, 20 min, 4 C). Supernatant (cytosolic fraction)
was discarded and samples were resuspended in lysis buffer. Sam-
ples were sonicated 10 s/3 times and then centrifuged
(12,000 rpm, 20 min, 4 C). Finally, the supernatant was stored at
20 C.
Once the proteins have been lysated, following the three proto-
cols previously described, protein concentration determination
was carried out by using Bradford assay and BSA as protein stan-
dard. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) procedure was used to separate proteins according
to their molecular weight. Proteins were transferred to a PVDF
membrane blocked with 0.25% non-fat dry milk and then it was
incubated for 10 min with anti-PKC clone M110 (1:1000, Milli-
pore), or anti PKCd (1:1000, BD Biosciences). After three washes
with washing buffer (PBS + 0.1% Tween 20), the membrane was
incubated for 10 min with the secondary antibody anti-Mouse
IgG conjugated with horseradish peroxidase (GE Healthcare). A
chemiluminescence detection kit (SuperSignal West Femto; Pierce)
was used to determine protein expression levels. Relative protein
expression was calculated in relation to b-actin (0.3:1000, Milli-
pore) for cytosolic and membrane proteins. For experiments with
latrunculin, relative protein expression was calculated in relation
to b-tubulin (0.3:1000, Sigma Aldrich). Histone H1 expression
(1:1000, Millipore) was used to calculate relative protein expres-
sion for nuclear proteins.2.5. PKCd-nucleus co-localization by ﬂow cytometry
HMC-1560 cells were treated with 25 nM STI571 and 200 nM
latrunculin for 48 h. Then cells were ﬁxed with 4% PFA for
20 min at room temperature and permeabilized using
PBS + 5%BSA + 0.1%Triton X-100 for 1 h 30 min at room tempera-
ture. Then cells were incubated for 12 h in the presence of anti
PKCd (1:1000, BD Biosciences). After PBS wash, primary antibody
was detected with FITC-conjugated secondary antibody (Goat Anti
Mouse IgG, IgM, IgA Biotin Conjugated, 1:1000, Millipore). For pro-
pidium iodide staining, the Coulter DNA Prep™ Stain (Beckman
Coulter) was used for 2 min at 37 C. ImageStream imaging ﬂow
cytometer (Amnis Corporation, Seattle, WA) was used in this study.
A total of 10,000 events were collected per sample and IDEAS soft-
ware (Amnis Corporation) was used for analysis.2.6. Apoptotic and necrotic cell death determination by ﬂow cytometry
Apoptosis was detected by Annexin-V-FITC/PI staining using
the Cell Lab ApoScreen™ Annexin V kit. The cells were incubated
with 25 nM STI571 for 48 h. Then cells were prepared exactly fol-
lowing manufacturer’s instructions assay and Amnis Corporation
IS-100 ﬂow cytometer was used.
Fig. 1. Effect of STI571 treatment and PKC activation on cytosolic cPKC and PKCd levels in HMC-1560 and HMC-1560,816 cell lines. (A and D) Show a representative experiment
of each condition in HMC-1560 and HMC-1560,816, respectively. (B and C) Represent cytosolic cPKC and PKCd levels for HMC-1560 cell line, whereas (E and F) represent cytosolic
cPKC and PKCd levels for HMC-1560,816 cell line. Protein levels are represented in relation with b-actin cytosolic levels. Mean ± SEM of three experiments. (*) Signiﬁcant
differences between untreated and treated cells.
Fig. 2. Effect of STI571 treatment and PKC activation on nuclear PKCd levels in
HMC-1560 and HMC-1560,816 cell line. (A and C) Show a representative experiment of
each condition in HMC-1560 and HMC-1560,816, respectively. (B) HMC-1560 and (D)
HMC-1560,816 nuclear PKCd expression was represented in relation with Histone H1
protein band intensity. Mean ± SEM of three experiments. (*) Signiﬁcant differences
between untreated and treated cells.
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GeneSilencer (Genlantis) was composed by the transfection
reagent and the diluent. Manufacturer’s instructions were followed
carefully. On the day of transfection two solutions were prepared.
On the one hand, solution A, composed by: diluent, FBS/Antibiotic-
free IMDMmedium and PKCd siRNA. Control siRNA (sc-37007) was
used as negative control for evaluating siRNA off-target effects. On
the other hand, solution B was composed by transfection reagent
diluted in FBS/Antibiotic-free IMDM medium. Solutions A and B
were mixed and incubated for 5 min at room temperature. HMC-
1560 cells were incubated in a total volume of 500 lL in FBS/Anti-
biotic-free IMDM medium. Cellular concentration was 2  106/
ml. 500 lL of IMDM (supplemented with 20% FBS and Penicillin/
Streptomycin 2x) were added to the HMC-1560 cells after 5 h trans-
fection. 19 h after cells were incubated with 25 nM STI571 for 48 h.2.8. Statistical analysis
Results were analyzed using the ANOVA and Student’s t-test for
unpaired data. A probability level of 0.05 or smaller was used for
statistical signiﬁcance. Results were expressed as the mean ± SEM.3. Results
Several experiments were carried out in order to determine
STI571-induced cell death relationship with PKC activity in HMC-
1 cell lines. First, STI571 effect over PKC expression was deter-
mined by Western blot. Fig. 1A and B shows that STI571, PMA
and STI571 + PMA treatments do not modify cytosolic classical
PKC (cPKC) levels in HMC-1560 cell line. The expression of the
PKC isoform PKCd, widely related with cell death and with DNA
damage through caspase-3 apoptotic pathway, was also studied
[32–35]. Contrary to STI571 effects previously observed in cPKC
isoforms, STI571 treatment induces a decrease of cytosolic PKCd
levels, from 1 to 0.2 ratio intensity values (Fig. 1A and C). This neg-
ative STI571 effect prevails even after PMA treatment, whereas
PMA alone does not modify cytosolic PKCd levels. This experiment
was also performed in the HMC-1560,816 cell line. In this case,
STI571 induces a signiﬁcant increase of cPKC levels (protein levels
are two-fold higher than in untreated cells), whereas PMA treat-
ment causes a decrease of cPKC expression (Fig. 1D and E). How-
ever, no modiﬁcations were observed after STI571 + PMA
treatment. In addition, STI571 incubation does not modify cyto-
solic PKCd levels in HMC-1560,816 cells (Fig. 1D and F), while PMA
induces a signiﬁcant decrease of cytosolic PKCd expression (ratio
intensity values fall down from 1 to 0.3). Besides, STI571 prevents
this negative PMA effect. Therefore it seems that both cPKC and
PKCd move from the cytosol to other localizations after HMC-1
cells treatment.
Since PKCd translocation to the nucleus is frequent after apop-
totic stimulation, the next step was to determine nuclear PKCd lev-
els. As Fig. 2A and B shows, PKCd translocates to the nucleus after
STI571 treatment in HMC-1560 cell line. Nuclear levels signiﬁcantly
increase from 1 to 3 (ratio intensity values). Besides, PKC activation
with PMA does not have any effect by itself and does not prevent
nuclear PKCd translocation (Fig. 2A and B). In HMC-1560,816 cell line,
PMA induces a signiﬁcant decrease on nuclear PKCd levels (Fig. 2C
Fig. 3. Effect of STI571 treatment and PKC activation on plasma membrane cPKC and PKCd levels in HMC-1560 and HMC-1560,816 cell line. (A and C) Show a representative
experiment of each condition in HMC-1560 and HMC-1560,816, respectively. HMC-1560 (B) and HMC-1560,816 (E) plasma membrane PKCd expression was represented in relation
with b-actin plasma membrane expression. (D) Plasma membrane cPKC expression in relation with b-actin in HMC-1560,816 cell line. Mean ± SEM of three experiments. (*)
Signiﬁcant differences between untreated and treated cells.
Fig. 4. Effect of STI571 on cytosolic PKCd levels in HMC-1560 cell line-latrunculin
incubated. (A) Is a representative experiment of each condition. (B) Represents
cytosolic PKCd levels for HMC-1560 cell line. Mean ± SEM of three experiments. (*)
Signiﬁcant differences between untreated and treated cells.
Fig. 5. Effect of STI571 on nuclear PKCd levels in HMC-1560 cell line-latrunculin
incubated. (A) Representative experiment of each condition. (B) Nuclear PKCd
expression was represented in relation with Histone H-1 band intensity. Mean ± -
SEM of three experiments. (*) Signiﬁcant differences between untreated and
STI571-treated cells. (#) Signiﬁcant differences between STI571 and
STI571 + latrunculin treated cells.
A. Tobío et al. / Cellular Immunology 293 (2015) 104–112 107and D). Therefore, nuclear PKCd levels are increased after STI571
treatment in HMC-1560 cells. Nuclear cPKC levels were not ana-
lyzed since in a previous paper we have demonstrated that cPKC
isoforms do not translocate to the nucleus [25].
Plasma membrane is one of the most common subcellular
spaces for PKC translocation. Therefore, PKCd levels were also stud-
ied in this localization [36]. As Fig. 3A and B shows, STI571 does not
cause PKCd membrane translocation, since protein levels are sig-niﬁcantly diminished. Besides, STI571 + PMA co-treatment induces
a signiﬁcant decrease of PKCdmembrane levels, whereas PMA does
not have any effect by itself. As Fig. 3C and D shows, PMA increases
cPKC levels on plasma membrane in HMC-1560,816 cell line. How-
ever, PKC activator diminishes PKCd levels (Fig. 3C and E), as hap-
pens in the cytosol and in the nucleus.
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ton. On the one hand, STI571 apoptotic effect is associated with
actin cytoskeleton alteration in HMC-1560 cell line, accompanied
by actin ﬁlamentous aggregation and actin polymerization
decrease [37]. On the other hand, it was described that PKC iso-
forms binding to F-actin enhances isozymes activity [38]. In addi-
tion to F-actin, PKC isoforms can be associated with other
cytoskeletal proteins as vimentin and cytokeratins [39]. In order
to determine if actin cytoskeleton participates in STI571-induced
nuclear PKCd translocation, latrunculin effect was studied in cyto-
solic and nuclear fractions. First, latrunculin, which affects actin
cytoskeleton by sequestering (monomeric) G-actin [40], effect
was checked in the presence of STI571. As Fig. 4A and B shows,
latrunculin partially inhibits STI571 effect over PKCd cytosolic
expression, since PKCd levels up from 0.2 to 0.5 ratio intensity val-
ues. Moreover, latrunculin does not have any effect by itself. At
nuclear level, latrunculin partially inhibits PKCd translocation
induced by STI571, since intensity values fall from 3 to 1.8
(Fig. 5A and B). To conﬁrm these results, nuclear PKCd transloca-
tion was determined in HMC-1560 cell line by using a double-stain-
ing technique (FITC for PKC and propidium iodide for nucleus). As
expected, STI571 induces nuclear PKCd translocation (Fig. 6). The
similarity of both dyes (FITC and propidium iodide) is signiﬁcantly
higher in the presence of STI571 (Fig. 6B). The percentage of
nuclear PKCd translocated cells in STI571 treated cells is 87%
(Fig. 6E). Latrunculin does not produce any effect by itself
(Fig. 6C and E). However, the percentage of translocated cells
decreases from 87% to 30% when STI571 is incubated in the pres-
ence of latrunculin. These results are consistent with those
obtained by Western blot.Fig. 6. Determination of PKCd-nucleus co-localization by ﬂow cytometry in HMC-1560 cel
each condition in brightﬁeld and composite (FITC and propidium iodide) channels are sh
Fig. 6E. (*) Signiﬁcant differences between untreated and treated cells. (#) Signiﬁcant diIt is well known that STI571 has cytotoxic effect against HMC-
1560, however the pathways activated by STI571 and the role of
PKCd are still poorly understood. We therefore next investigated
the effect of STI571 on HMC-1560 cells by using the Annexin V-FITC
technique. This method allows us to determine live, apoptotic and
necrotic cells distribution. As Fig. 7A and C shows in control condi-
tions (untreated cells) that the percentage of viable cells is 70%,
while the rest, 30%, are necrotic cells. After STI571 treatment,
40% of the total are live cells, and apoptotic and necrotic popula-
tions are the 39% and 15%, respectively (Fig. 7B and C). Next, PKCd
role on apoptosis induced by STI571 was studied by PKCd silencing
in HMC-1560 cell line. The ﬁrst step was to evaluate PKCd silencing
method effectiveness, by using a tested siRNA PKCd [41–44]. As
Fig. 8A and B shows, PKCd cytosolic expression signiﬁcantly
decreases (from 0.46 to 0.16) in PKCd-silenced cells. Thus, a silenc-
ing around 65% is obtained. Then, STI571 cytotoxic effect was
determined in PKCd-silenced cells (Fig. 9). Surprisingly, apoptotic
cell death induced by this tyrosine kinase inhibitor disappears in
PKCd-silenced cells, since apoptotic population signiﬁcantly falls
down from 40% to 15% and the live population increases in the
same percentage (Fig. 9B and C). Therefore these data indicate that
STI571 mechanism of action is dependent of PKCd.4. Discussion
Results shown in this paper demonstrate that c-kit inhibition is
clearly linked to PKC activity. In the HMC-1560 cell line, long-term
PKC activation does not induce a decrease neither on cPKCs nor
PKCd cytosolic levels. This observation is in accordance with a pre-
vious study in which PKC was only activated for 10 min and nol line. (A, B, C and D) Show a representative histogram of each condition. Two cells of
own below the histograms. The mean ± SEM of three experiments is represented in
fferences between STI571 and STI571 + latrunculin treated cells.
Fig. 7. Determination of live, apoptotic and necrotic HMC-1560 cell line treated with 25 nM STI571. Live (botton left panel of each graph), apoptotic (botton right panel of each
graph) and late apoptotic/necrotic (upper panel of each graph) cells were detected by Annexin-V-FITC/PI staining. Graphs represent one of three repeated experiments: (A)
untreated cells and (B) STI571-treated cells. The mean ± SEM of three experiments is represented in Fig. 7C. (*) Represents signiﬁcant differences between untreated and
treated cells.
Fig. 8. Determination of PKCd silencing efﬁciency by Western blot analysis in HMC-
1560 cell line. (A) Shows a representative image of each condition. (B) Mean ± SEM of
three experiments. Cytosolic PKCd levels were represented respect to cytosolic b-
actin expression. (*) Signiﬁcant differences between no-silenced and PKCd-silenced
cells.
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PMA treatment induces plasma membrane cPKCs translocation in
the HMC-1560,816 cell line. This opposite PMA effect observed in
both HMC-1 cell lines could be related with PKC capacity of c-kit
phosphorylation (at two speciﬁc serine residues) previously
described [45–47]. In this sense, the PKC activation induced by
PMA can produces c-kit phosphorylation in a different way in each
HMC-1 line and as consequence different cPKCs levels. Also, it was
observed that c-kit inhibition induces nuclear PKCd translocation
in HMC-1560 cell line, which is accompanied with a decrease on
cytosolic and membrane levels. Moreover, it has been demon-
strated that PKCd translocation to the nucleus takes place through
actin cytoskeleton, since PKCd translocation is lower after actin dis-
ruption. This fact could indicate that apoptotic effect due to c-kit
inhibition is actin cytoskeleton-dependent. Speciﬁcally, it has been
described that apoptotic effect induced by c-kit inhibition is
accompanied with actin ﬁlamentous instability in colon adenocar-
cinoma cells [37]. Also, it was observed that nuclear PKCd translo-
cation induced by c-kit inhibition predominates even after PKC
activation. Besides, STI571 effect over other different kinases,
including PKCe and protein tyrosine kinase 2 (PyK2), has been pre-
viously described in T98G malignant glioma cells [20]. Based on
these ﬁndings, these kinases might be implicated as targets for
the drug.
Fig. 9. Determination of live, apoptotic and necrotic population in PKCd-silenced HMC-1560 cells treated with 25 nM STI571. Live (botton left panel of each graph), apoptotic
(botton right panel of each graph) and late apoptotic/necrotic (upper panel of each graph) cells were detected by Annexin-V-FITC/PI staining. Graphs represent one of three
repeated experiments: (A) untreated cells and (B) STI571-treated cells. The mean ± SEM of three experiments is represented in Fig. 9C. (*) Statistical signiﬁcance difference
between no-silenced and PKCd-silenced HMC-1560 cells.
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levels, since increases cPKCs but does not have any effect on PKCd
expression. The positive effect of STI571 over cPKC expression
might be related with the fact that c-kit is an excellent activator
of cPKCs through phospholipase C c activation, leading to DAG
release, Ca2+ and PKC activation [48]. In the HMC-1560,816 cell line,
cPKC levels increase induced by STI571 can be related with a
decrease in the spontaneous histamine release and with an
increase in the histamine released after cellular alkalinisation pre-
viously described [49]. Therefore, STI571 enhancer effect over cPKC
cytosolic expression might be related with HMC-1560,816 activation.
On the other hand, PKC activation induces membrane cPKC trans-
location in these cells, which is in agreement with cytosolic cPKC
levels decrease. However, cytosolic cPKC levels are not modiﬁed
after PMA and STI571 simultaneous addition. This fact might indi-
cate a possible competitive action between both compounds (PMA
and STI571), whereas under these conditions cellular activation is
not affected [49]. This relationship does not exist in HMC-1560 cell
line, since tyrosine kinase inhibition does not have any effect over
cPKC isoforms and only PKCd isoform is modiﬁed. Moreover, in
HMC-1560,816 cell line, PMA induces a decrease of both cytosolic
cPKC and PKCd levels. In this case, cPKC isoforms translocate to
the membrane when they are activated. It is important to note thatthe plasma membrane is a subcellular localization very common
when this kinase is activated [36,50]. On the other hand, PKCd iso-
form does not translocate to the plasma membrane or to the
nucleus, in fact, membrane PKCd levels decrease when PMA is
added. Hence, this suggests an intense down-regulation of this iso-
form in the HMC-1560,816 cell line. Besides, cytosolic PKCd expres-
sion regulation when this kinase is activated was also described
in liver tumor, suggesting an inhibitory role on tumor cell prolifer-
ation [51]. In HMC-1560,816 cell line, PKCd expression down-regula-
tion is not only observed in the cytosol but also in plasma
membrane and nuclear fractions. It has been previously described
that PMA (30 min) induces protein translocation from the cytosol
to the membrane and also increases cell immunological response
of RBL-2H3 cells. However, PKC activation for (18 h) induces a
complete absence of degranulation and the absence of cytosolic
PKC is observed, which is in accordance with the present results
[52]. The opposite effect of PKC activation in cPKC and PKCd cyto-
solic expression in both cellular lines can explain the contrary
effect on the cellular activation, quantiﬁed as histamine release,
previously described [25,31].
Results obtained in the present work conﬁrm that long-term
PMA exposure implies the degradation of a speciﬁc isoform, PKCd,
in HMC-1560,816 cell line. Taking into account that PKC has a central
A. Tobío et al. / Cellular Immunology 293 (2015) 104–112 111role in mast cell activation and degranulation, these results might
indicate some speciﬁc role of PKCd in HMC-1560,816 cell line activa-
tion that is not present in the other cell line HMC-1560 [49,53–56].
On the contrary, nuclear PKCd translocation is closely related with
cell death in HMC-1560 cells. As it was described in other studies
PKCd translocates from the cytoplasm to the nucleus in response
to apoptotic stimuli, STI571 in our case [17]. Thus, our results con-
ﬁrm that apoptosis induced by c-kit inhibition takes place through
PKCd translocation. In this sense, several intracellular changes
might be occur in STI571-induced cell death related to nuclear
PKCd translocation, since caspase-3, mitogen activated protein
kinases (MAPKs) and PARP are proteins also involved in STI571-
apoptotic cell death [57,58]. It is important to note that actin cyto-
skeleton plays an important role in this translocation. Therefore,
this study demonstrates that apoptotic cell death induced by c-
kit inhibition is clearly PKCd-dependent in HMC-1560 cell line. In
this sense, the apoptotic effect induced by STI571 is three-fold
lower when PKCd expression is abolished. For this, it can be stated
that PKCd plays an essential role in apoptotic cell death STI571-
induced. This conclusion is of potential relevance, and should be
bear in mind in patients with STI571 treatment, since any factor
or secondary effect that could down-regulate PKCdmight diminish
three fold the apoptotic cell death induced by the tyrosine kinase
inhibitor STI571.
Hence, results showed in this paper clearly demonstrate that
apoptotic cell death induced by c-kit inhibitor STI571 is PKCd-
dependent in the HMC-1560 cell line. Also, PKCd isoform translo-
cates to the nucleus in response to c-kit inhibition and actin cyto-
skeleton integrity is essential to achieve this translocation in this
cell line. However, in HMC-1560,816 cell line, c-kit inhibitor STI571
increases cPKC levels and does not affect PKCd expression. In this
cellular line PKCd seems to be down-regulated.Authors’ contributions
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